PROMISE Score

Research use only

*More information at the bottom of the page The objective of this tool is to predict the probability of mortality at 90 days after admission in oncologic metastatic patients with active treatment and unscheduled admission. The data used was from the study PLANTOLOGY (NCT05534178 at https://clinicaltrials.gov/ct2/show/NCT05534178?term=plantology&draw=2&rank=1=) and approved by all the independent ethics committee at each center (Vall d'Hebron: PR(AG)92/2020).
All laboratory parameters (LDH, PMN, and albumin) were collected within 24-48 hours from admission.
The inclusion criteria were:
  • 1. Unplanned hospitalization
  • 2. Metastatic disease or unresectable
  • 3. On active treatment (last 6 months prior to admission).
  • 4. More than 18 years old.
Please select your patient characteristics:
ECOG (performance status)
Oncologic treatment response
LDH (U/L) (Lactate dehydrogenase)
PMN (10^9/L) (Polymorphonuclear leukocyte)
Albumin (g/dL)
*ECOG and Oncologic Treatment Response (based on clinical, radiological or tumor marker criteria) were collected at last ambulatory visit prior to admission.
*PR/CR: partial response/complete response; SD: stable disease/not evaluable; PD: progressive disease

Patient risk of 90-day mortality

Risk category

Performance of 90-day mortality prediction in your patient

Each probability has been classified into high, intermediate and low. The high, intermediate and low risk curves depict the distribution of the classified patients as density plots.
The overlap between the curves should be seen as the relative frequency that a predicted probability belongs to a given group. For example: A patient with 27% probability is very unlikely in the 'low risk' group (extreme value in the left tail) while very more likely in the 'intermediate risk' group (in the hump of the group distribution).

About the tool
To address the lack of standardized prognostic tools for hospitalized oncology patients, we initiated an observational prospective study at Vall d’Hebron Hospital and Vall d’Hebron Institute of Oncology (VHIO) during 2020. Dr. Mirallas in collaboration with colleagues from the medical oncology department, nutritionists, and nurses, we gathered data from over 1,500 patients admitted to our ward at Vall d’Hebron University Hospital. One year later, our findings were validated in collaboration with two additional institutions in Barcelona—Hospital del Mar and Hospital de la Santa Creu i Sant Pau.
The Odyssey Data Science Group from Vall d’Hebron Institute of Oncology performed the statistical analysis, modeling, and developed the web tool for clinical application. Our results, published in The Lancet Regional Health – Europe, introduce the PROMISE tool, designed to provide objective prognostic information for clinicians managing hospitalized cancer patients with advanced disease not in exclusive palliative care. We anticipate that this tool will significantly enhance physicians' ability to optimize care for hospitalized cancer patients and support medical decisions.
More information can be found at: PROMISE paper
Oriol Mirallas is a medical oncologist and clinical investigator specialized in Phase I Clinical Trials and Lung Cancer at the Vall d'Hebron Institute of Oncology (VHIO). Dr. Mirallas' research focuses on developing novel therapeutics for patients with cancer and prognostic tools essential for informed treatment decisions and patient care in advanced cancer.
“I realized during my second year of residency at Vall d’Hebron Hospital that prognosis for hospitalized oncologic patients lacked standardization, with many decisions made solely based on ECOG PS. I strongly believed that this approach needed improvement, leading to the initiation of Project PLANTOLOGY, which ultimately resulted in the creation of the PROMISE tool that I hope will help many patients and physicians”.

*This tool is intended solely for research purposes and is not intended for use in clinical diagnosis or patient management.
The Vall d'Hebron Institute of Oncology (VHIO) does not make any warranties, express or implied, regarding the accuracy, completeness, reliability, or suitability of the tool for any specific purpose.
Users are advised to exercise their own judgment and consult with appropriate healthcare professionals before making any decisions based on the output of this tool. VHIO assumes no liability for any decisions made or actions taken based on the information provided by this tool.
By using this tool, you acknowledge and agree to these terms.

Contact us at info.promise@vhio.net

Coded by Odyssey (Oncology Data Science Team in Vall d'Hebron Institute of Oncology) - Code available at GitHub